<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Featured Headlines Feed for ARQL</title>
    <link />
    <description>Headlines for ArQule, Inc.</description>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>Argotic Syndication Framework 2008.0.2.0, http://www.codeplex.com/Argotic</generator>
    <item>
      <title>Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Can</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/06/01/phase-2-study-results-for-tivantinib-in-combinatio/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Sat, 01 Jun 2013 19:20:14 GMT</pubDate>
    </item>
    <item>
      <title>ArQule Announces Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan f</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/06/3639658/arqule-announces-phase-2-study-results-for-tivantinib-in-combination-with-cetuxim.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Sat, 01 Jun 2013 19:05:40 GMT</pubDate>
    </item>
    <item>
      <title>ArQule, Inc. to Present at Jefferies 2013 Global Healthcare Conference</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/30/arqule-inc-to-present-at-jefferies-2013-global-hea/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Thu, 30 May 2013 08:50:14 GMT</pubDate>
    </item>
    <item>
      <title>10 ASCO '13 Abstracts You Can Read Right Now</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11923326/1/10-asco-13-abstracts-you-can-read-right-now.html.aspx?puc=aol&amp;cm_ven=aol&amp;source=itxwebtxt0000015</link>
      <author>TheStreet</author>
      <pubDate>Wed, 15 May 2013 18:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Narrower-than-Expected Loss at ArQule - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/99047/narrower-than-expected-loss-at-arqule.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Thu, 09 May 2013 13:05:01 GMT</pubDate>
    </item>
    <item>
      <title>ArQule Management Discusses Q1 2013 Results - Earnings Call Transcript</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1416021-arqule-management-discusses-q1-2013-results-earnings-call-transcript.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Wed, 08 May 2013 17:00:05 GMT</pubDate>
    </item>
    <item>
      <title>ArQule Reports First Quarter 2013 Financial Results</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/08/arqule-reports-first-quarter-2013-financial-result/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 08 May 2013 07:20:44 GMT</pubDate>
    </item>
    <item>
      <title>ArQule to Report First Quarter 2013 Financial Results on May 8, 2013</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/05/01/arqule-to-report-first-quarter-2013-financial-resu/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Wed, 01 May 2013 08:51:34 GMT</pubDate>
    </item>
    <item>
      <title>First Manhattan Responds to VIVUS Board Additions, Says Board Still Needs Overhaul</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/05/3547726/first-manhattan-responds-to-vivus-board-additions-says-board-still-needs-overhaul.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Wed, 01 May 2013 08:49:04 GMT</pubDate>
    </item>
    <item>
      <title>Early-Stage Clinical Data Highlights From AACR 2013</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1346911-early-stage-clinical-data-highlights-from-aacr-2013.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Wed, 17 Apr 2013 07:07:26 GMT</pubDate>
    </item>
    <item>
      <title>Data on ArQule's ARQ 092 - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96766/data-on-arqules-arq-092.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Wed, 10 Apr 2013 16:10:01 GMT</pubDate>
    </item>
    <item>
      <title>ArQule’s Novel AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase 1 Tri</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/04/09/arqules-novel-akt-pathway-inhibitor-arq-092-demons/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Tue, 09 Apr 2013 12:20:37 GMT</pubDate>
    </item>
    <item>
      <title>ArQule Regains ARQ 092 Rights - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/96128/arqule-regains-arq-092-rights.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Tue, 02 Apr 2013 17:40:01 GMT</pubDate>
    </item>
    <item>
      <title>ArQule Regains Worldwide Rights to AKT Program</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/04/01/arqule-regains-worldwide-rights-to-akt-program/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Mon, 01 Apr 2013 12:42:55 GMT</pubDate>
    </item>
    <item>
      <title>These 4 Biotech Stocks Have Upside, Says Burrill's Senior Analyst</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1299321-these-4-biotech-stocks-have-upside-says-burrill-s-senior-analyst.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Mon, 25 Mar 2013 16:02:23 GMT</pubDate>
    </item>
    <item>
      <title>ArQule's Loss Narrower than Expected  - Analyst Blog</title>
      <link>http://www.fool.com/news/xt/zacks/www.zacks.com/stock/news/95114/arqules-loss-narrower-than-expected.aspx?source=itxwebtxt0000015</link>
      <author>Zacks</author>
      <pubDate>Tue, 19 Mar 2013 14:58:01 GMT</pubDate>
    </item>
    <item>
      <title>ArQule Management Discusses Q4 2012 Results - Earnings Call Transcript</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1274531-arqule-management-discusses-q4-2012-results-earnings-call-transcript.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Thu, 14 Mar 2013 14:10:07 GMT</pubDate>
    </item>
    <item>
      <title>ArQule Reports Fiscal 2012 Year End and Fourth Quarter Results</title>
      <link>http://www.fool.com/news/xt/aol-daily-finance/www.dailyfinance.com/2013/03/14/arqule-reports-fiscal-2012-year-end-and-fourth-qua/.aspx?source=itxwebtxt0000015</link>
      <author>DailyFinance</author>
      <pubDate>Thu, 14 Mar 2013 07:17:06 GMT</pubDate>
    </item>
    <item>
      <title>Earnings Scheduled For March 14, 2013</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/earnings/13/03/3415578/earnings-scheduled-for-march-14-2013.aspx?source=itxwebtxt0000015</link>
      <author>Benzinga</author>
      <pubDate>Thu, 14 Mar 2013 04:25:22 GMT</pubDate>
    </item>
    <item>
      <title>George Zavoico: Biotech Stocks That Deserve A Closer Look</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1258441-george-zavoico-biotech-stocks-that-deserve-a-closer-look.aspx?source=itxwebtxt0000015</link>
      <author>Seeking Alpha</author>
      <pubDate>Fri, 08 Mar 2013 03:15:38 GMT</pubDate>
    </item>
  </channel>
</rss>
